Meet-the-Professor Session:
179. B-lactam/ B-lactamase Inhibitor Combinations: Which one?
Saturday, October 6, 2018: 7:15 AM-8:15 AM
Room: S 214-216

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • define the differences in activity between ceftazidime/avibactam, ceftolozane/tazobactam, meroepenm/vaborbactam, and imipenem/relebactam
  • define the correct role for each agent on the hospital formulary

Target Audience: Investigators, Pharmacists, Scientists

Tracks: Pediatric ID, Adult ID


Moderators:  David R. Andes, M.D., FIDSA, University of Wisconsin School of Medicine and Public Health , Cesar Arias, MD, PhD, FIDSA, University of Texas Health Science Center at Houston and Robert Bonomo, MD, Louis Stokes Cleveland VA Medical Center

CME Credits: Maximum of 1.00 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE

ACPE Number: 0221-9999-18-248-L01-P

Disclosures:

D. R. Andes, Amplyx Pharmaceuticals, Inc.: Grant Investigator , Research grant .

C. Arias, Merck & Co., Inc.: Grant Investigator , Research support . MeMed: Grant Investigator , Research support . Allergan: Grant Investigator , Research support .

R. Bonomo, None

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.